Barrington Research Maintains Outperform on Lifecore Biomedical, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Barrington Research analyst Michael Petusky has maintained an Outperform rating on Lifecore Biomedical (NASDAQ:LFCR) but lowered the price target from $11 to $10.
September 01, 2023 | 3:45 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Barrington Research has maintained an Outperform rating on Lifecore Biomedical but lowered the price target from $11 to $10.
The news is directly about Lifecore Biomedical and is likely to influence investor sentiment. While the Outperform rating is positive, the lowering of the price target may have a neutralizing effect, hence the score of 0.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100